ReviewThe European respiratory journal2012
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Review in The European respiratory journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 111 citations in OpenAlex.
- Bioactive goldenseal (Hydrastis canadensis) fraction suppresses multidrug-resistant Pseudomonas aeruginosa in a rat burn wound model: oral and topical administration.Scientific reports · 2026Article
- Repurposing Tirazone as an effective quorum-sensing inhibitor against Pseudomonas aeruginosa virulence and biofilm formation.The Journal of antibiotics · 2026Article
- Anti-pyocyanin Antibody Exhibits Cytotoxicity Protective Effects on Macrophages: A Promising Innovative Therapeutic Approach forACS pharmacology & translational science · 2025Article
- Chromatographic fingerprinting and antibiofilm effect of Ziziphus jujuba fraction on Pseudomonas aeruginosa.AMB Express · 2025Article
- A Systematic Hierarchical Virtual Screening Model for RhlR Inhibitors Based on PCA, Pharmacophore, Docking, and Molecular Dynamics.International journal of molecular sciences · 2024Article
- Phage therapy: breathing new tactics into lower respiratory tract infection treatments.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Enzyme-Linked Lipid Nanocarriers for Coping Pseudomonal Pulmonary Infection. Would Nanocarriers Complement Biofilm Disruption or Pave Its Road?International journal of nanomedicine · 2024Article
- Review
- Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Inulin Prebiotic Protects against LethalNutrients · 2023Article
- Micafungin effect on Pseudomonas aeruginosa metabolome, virulence and biofilm: potential quorum sensing inhibitor.AMB Express · 2023Article
- Anti-quorum sensing potential of selenium nanoparticles against LasI/R, RhlI/R, and PQS/MvfR inFrontiers in molecular biosciences · 2023Article
- Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms.BioMed research international · 2023Review
- Structural Considerations for Building Synthetic Glycoconjugates as Inhibitors for Pseudomonas aeruginosa Lectins.ChemMedChem · 2022Review
- Discovery of Marine Natural Products as Promising Antibiotics againstMarine drugs · 2022Review
- Isolation and characterization of two homolog phages infectingFrontiers in microbiology · 2022Article
- Sodium Selenite Enhances Antibiotics Sensitivity ofAntioxidants (Basel, Switzerland) · 2021Article
- Growing emergence of drug-resistantIranian journal of basic medical sciences · 2021Review
- Ruthenium-centred btp glycoclusters as inhibitors forRSC advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Pseudomonas aeruginosa chronically infects patients with cystic fibrosis and is associated with greater morbidity. There has been limited progress on the clinical development of new antibiotics with novel modes of action. This review addresses some of the latest research developments on the exploitation of candidate adjuvant therapeutic agents that may act alongside conventional antibiotics as an alternative therapeutic strategy. After considering key mechanisms this opportunistic pathogen employs to control virulence, the progress of various strategies including the inhibition of quorum sensing, efflux pumps and lectins, and the use of iron chelators, bacteriophages, immunisation and immunotherapy is reviewed. Both therapeutic approaches in early development and clinical phase are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.